NeurAxis Achieves New Milestone with FDA Clearance
NeurAxis, Inc. has recently celebrated a significant accomplishment in the realm of medical technology with the announcement of receiving FDA 510(k) clearance for its innovative IB-Stim™ Nonimplanted Nerve Stimulator. This groundbreaking device is designed specifically to aid in the relief of functional abdominal pain, particularly targeting painful conditions associated with irritable bowel syndrome (IBS) in adolescents aged 8 to 21 years old.
The Expansion of IB-Stim’s Addressable Market
With this new FDA clearance, NeurAxis is poised to expand its addressable market by an impressive 75%, which translates into increased opportunities for the company and improved treatment options for patients. Brian Carrico, the President and Chief Executive Officer of NeurAxis, expressed enthusiasm about the implications of this clearance, stating that not only does it broaden the market for IB-Stim, but it also allows for an increase in the use of devices per patient, now indicated as four devices for optimal treatment.
Strong Evidence Supporting New Indications
This achievement can be attributed to the robust body of published research that NeurAxis has leveraged to advocate for this new indication. The mounting evidence has contributed to the growing acceptance of NeurAxis's PENFS technology. This technology stands out in a market where viable options for treating abdominal pain, particularly in the pediatric population, are limited.
Challenges in Traditional Treatments
Historically, pediatric patients suffering from abdominal pain-related disorders have faced a dearth of FDA-approved drug therapies. Most existing pharmacologic treatments are often off-label, leading to serious side effects without sufficient scientific validation of their efficacy. This gap in treatment options starkly highlights the importance of IB-Stim as a viable alternative for management.
Future Prospects and Development
NeurAxis remains committed to advancing its innovative technologies and expanding its reach. The recent establishment of a new CPT Category I code by the American Medical Association, effective in 2026, further underscores the company’s potential for growth. It sets the stage for increased payer coverage and broader acceptance within the medical community, facilitating better accessibility for patients in need of this advanced treatment.
Company’s Commitment to Evidence-Based Medicine
NeurAxis is dedicated to enhancing the scientific landscape surrounding its therapies. The organization focuses on leveraging evidence-based medicine to increase the adoption of its therapies, particularly the IB-Stim. The company is also actively conducting additional clinical trials aimed at exploring PENFS applications in various pediatric and adult conditions, which continue to present significant unmet healthcare needs.
About NeurAxis, Inc.
NeurAxis, Inc. is a pioneering medical technology company specializing in neuromodulation therapies designed to address chronic and debilitating conditions in both children and adults. Through its commitment to advancing science and promoting evidence-based practices, NeurAxis aims to make a significant impact in the healthcare field and improve the quality of life for many.
Frequently Asked Questions
What is IB-Stim?
IB-Stim is a non-surgical device that employs electrical impulses to aid in the relief of functional abdominal pain associated with IBS in adolescents.
How does the new FDA clearance affect NeurAxis?
The new FDA clearance allows NeurAxis to expand its market by 75% and increases the number of devices that can be used per patient from one to four.
Why is IB-Stim important for pediatric patients?
IB-Stim provides a non-drug therapeutic option for pediatric patients suffering from abdominal pain, offering a safer alternative to pharmacological treatments that may have harmful side effects.
What future developments can we expect from NeurAxis?
NeurAxis is actively conducting clinical trials for PENFS technology in various conditions, and it also anticipates enhanced payer coverage and broader acceptance of IB-Stim following its recent achievements.
Where can I find more information about NeurAxis?
For more information about NeurAxis and its products, you can visit their official website at http://neuraxis.com.
